RIBON THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ribontx.com
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05215808
- Locations
- 🇦🇺
Veracity Clinical Research, Woolloongabba, Queensland, Australia
🇦🇺CMAX Clinical Research Pty Ltd, Adelaide, Australia
🇳🇿Optimal Clinical Trials, Auckland, New Zealand
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
- Conditions
- Advanced Squamous Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05127590
- Locations
- 🇺🇸
Helen F. Graham Cancer Center (Christiana Care), Newark, Delaware, United States
🇺🇸Cancer Treatment Centers of America, Newnan, Georgia, United States
🇺🇸Hematology and Oncology Clinic, Baton Rouge, Louisiana, United States
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Ribon Therapeutics, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT04053673
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸SCRI-Denver/HealthOne, Denver, Colorado, United States
🇺🇸Yale Cancer Center, Yale University, New Haven, Connecticut, United States